#152939

Anti-Lewis y/b hapten [NCRC37]

Please Enter Your Email ID
Email ID

Cat. #152939

Anti-Lewis y/b hapten [NCRC37]

Cat. #: 152939

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Sialyltetraosylceramiden antigen on colorectal tumor cell surface

Class: Monoclonal

Application: ELISA ; FACS ; IHC ; Fn

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Lindy Durrant

Institute: University of Nottingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-Lewis y/b hapten [NCRC37]
  • Research fields: Immunology;Tissue-specific biology
  • Clone: NCRC37
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; FACS ; IHC ; Fn
  • Description: Blood group related antigens are a group of carbohydrate determinants present on both glycoproteins and glycolipids. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Lewis- y/b is a cell surface carbohydrate blood group antigen expressed at very low levels in normal tissue, but often found to be over-expressed on breast, lung, colon and ovarian cancer cells. Lewis-y antigen, a difucosylatedtetrasaccharide, is found on type 2 blood group oligosaccharides. The antibody, NCRC37, is a pan-reactive, anti-colorectal tumour antibody and binds strongly to coloretal tumour cells and to post mortem cryopreserved tissues of brain, spleen, heat, lung, kidney, testes, oesophagus or stomach. Lewis y antigen has been evaluated as a clinical marker for the diagnosis and prognosis of cholangiocarcinoma, hepatocellular carcinoma and breast cancer.
  • Immunogen: Tissue cultured colorectal tumor cell lines (C170, C146, Colo205, and JW)
  • Isotype: IgG1
  • Myeloma used: NS0
  • Recommended controls: C14 (NCRC10)

Target Details

  • Target: Sialyltetraosylceramiden antigen on colorectal tumor cell surface
  • Tissue cell line specificity: C14 (NCRC10)
  • Target background: Blood group related antigens are a group of carbohydrate determinants present on both glycoproteins and glycolipids. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Lewis- y/b is a cell surface carbohydrate blood group antigen expressed at very low levels in normal tissue, but often found to be over-expressed on breast, lung, colon and ovarian cancer cells. Lewis-y antigen, a difucosylatedtetrasaccharide, is found on type 2 blood group oligosaccharides. The antibody, NCRC37, is a pan-reactive, anti-colorectal tumour antibody and binds strongly to coloretal tumour cells and to post mortem cryopreserved tissues of brain, spleen, heat, lung, kidney, testes, oesophagus or stomach. Lewis y antigen has been evaluated as a clinical marker for the diagnosis and prognosis of cholangiocarcinoma, hepatocellular carcinoma and breast cancer.

Applications

  • Application: ELISA ; FACS ; IHC ; Fn

Handling

  • Format: Liquid
  • Concentration: 1.14 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Durrant et al. 2006. Cancer Res. 66(11):5901-9. PMID: 16740730.
  • A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis.
  • Durrant et al. 1993. Hybridoma. 12(6):647-60. PMID: 7507082.
  • Development of second generation monoclonal antibodies recognising Lewisy/b antigen by anti-idiotypic immunisation.